Share

Such Great Heights

ENDO_2023_4C Pediatric growth hormone deficiency treatments could soon be painless. Fernando Cassorla, MD, is traveling from Chile to Chicago to present research at ENDO 2023 that could potentially change the way pediatric hormone treatments are administered. If a pill could replace painful injections, patients and caregivers alike can finally wipe away their tears. A convenient, well...
Share

FDA Approves Once-Weekly Sogroya® for the Treatment of Children Living with Growth Hormone Deficiency

The U.S. Food and Drug Administration (FDA) last month approved a new indication for somapacitan-beco injection 5 mg, 10 mg, or 15 mg for the treatment of children aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone. Novo Nordisk is marketing the treatment as Sogroya® The FDA approval...
Share

The “Congenital” Scientist

EN_01_2023_US_FINALCOVER Honored by both the Endocrine Society and the European Society of Endocrinology with the 2023 Transatlantic Alliance Award, George Chrousos, MD, ScD, has made significant contributions to endocrine research on both sides of the Atlantic! Endocrine News speaks with Chrousos about what this award means to him, conducting pioneering research on two different continents, the...
Share

Shock to the System: Pediatric Type 1 Diabetes Patients and Trauma

A new study seems to suggest that while trauma and post-traumatic stress syndrome are common in kids with type 1 diabetes, they have little to no impact on their diabetes self-management. However surprising this finding may be to researchers, it further stresses the need for multidisciplinary teams to care for these patients. Children suffering traumatic...
Share

European Medicine Agency’s CHMP Grants Positive Opinion to Long-Acting Growth Hormone for Patients with Pediatric Growth Hormone Deficiency

In November, the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorization for Ascendis Pharma’s lonapegsomatropin (TransCon hGH), a long-acting once-weekly, transiently pegylated somatropin that in the body releases somatropin, indicated for growth failure in children and adolescents aged from 3 years...